Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revvity (RVTY – Research Report) and Candel Therapeutics (CADL – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Revvity (RVTY)
In a report released today, Daniel Arias from Stifel Nicolaus maintained a Hold rating on Revvity, with a price target of $110.00. The company’s shares closed last Friday at $83.70.
According to TipRanks.com, Arias is a 1-star analyst with an average return of
Revvity has an analyst consensus of Moderate Buy, with a price target consensus of $114.60, representing a 33.7% upside. In a report released today, TipRanks – xAI also reiterated a Hold rating on the stock with a $97.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Candel Therapeutics (CADL)
Canaccord Genuity analyst John Newman maintained a Buy rating on Candel Therapeutics today and set a price target of $25.00. The company’s shares closed last Friday at $4.99.
According to TipRanks.com, Newman is a 2-star analyst with an average return of
Candel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.60, implying a 269.0% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $16.00 price target.
